TX Judge’s Dismissal Of IRA Case Puts New Argument In Legal Fray

A Texas district court’s recent dismissal of a case against drug price negotiation in Medicare inserts a new argument into the ongoing legal fray against implementation of the Inflation Reduction Act’s most notable drug price control: Providers who claim they will also suffer from the lower Part B prices CMS negotiates with drug makers will need to take their complaints directly to Medicare before going to court. The dismissal can be appealed, but the three plaintiffs -- the Pharmaceutical Research...